Bio-Techne Corporation

NasdaqGS:TECH Voorraadrapport

Marktkapitalisatie: US$10.9b

Bio-Techne Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Bio-Techne is de winst gegroeid met een gemiddeld jaarlijks percentage van 4.9%, terwijl de Life Sciences industrie de winst jaarlijks groeide met 11.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 10.6% per jaar. Het rendement op eigen vermogen van Bio-Techne is 7%, en het heeft een nettomarge van 12.9%.

Belangrijke informatie

4.9%

Groei van de winst

4.1%

Groei van de winst per aandeel

Life Sciences Groei van de industrie21.5%
Inkomstengroei10.6%
Rendement op eigen vermogen7.0%
Nettomarge12.9%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Recent updates

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Opbrengsten en kosten

Hoe Bio-Techne geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:TECH Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,17215143497
30 Jun 241,15916842997
31 Mar 241,15420341896
31 Dec 231,14522442793
30 Sep 231,14424740793
30 Jun 231,13728539792
31 Mar 231,12427141592
31 Dec 221,12026239091
30 Sep 221,11829240089
30 Jun 221,10627239287
31 Mar 221,07622536185
31 Dec 211,03021035080
30 Sep 2198517733476
30 Jun 2193114031271
31 Mar 2184818429667
31 Dec 2079917528266
30 Sep 2076024827165
30 Jun 2073922926765
31 Mar 2075518727365
31 Dec 1974519527164
30 Sep 197349326664
30 Jun 197149626262
31 Mar 1970312125760
31 Dec 186829624458
30 Sep 1866112823257
30 Jun 1864312621655
31 Mar 1861911219455
31 Dec 1759911418755
30 Sep 175777318354
30 Jun 175637617554
31 Mar 175417417051
31 Dec 165288215849
30 Sep 1651710114547
30 Jun 1649910413845
31 Mar 1648210513044
31 Dec 154659912544
30 Sep 1545610712143
30 Jun 1545210811541
31 Mar 1542710810138
31 Dec 144081168634
30 Sep 143801077132
30 Jun 143581116031
31 Mar 143451135430
31 Dec 133301145030

Kwaliteitswinsten: TECH heeft een grote eenmalige verlies van $53.6M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th September, 2024.

Groeiende winstmarge: De huidige netto winstmarges (12.9%) TECH } zijn lager dan vorig jaar (21.6%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van TECH is de afgelopen 5 jaar met 4.9% per jaar gegroeid.

Versnelling van de groei: De winstgroei TECH is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: TECH had het afgelopen jaar een negatieve winstgroei ( -38.9% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Life Sciences ( -4.7% ).


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 7% ) van TECH wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden